Triple-negative breast cancer represents one of oncology's most stubborn challenges — a subtype defined by the absence of estrogen, progesterone, and HER2 receptors that strips away the three most common therapeutic targets. For the roughly 15–20% of breast cancer patients with this diagnosis, the treatment calculus is shifting in meaningful ways, and understanding the current state of that shift matters for anyone tracking cancer survivorship and longevity outcomes.
This review in Acta Pharmacologica Sinica maps the transition from cytotoxic chemotherapy toward precision-directed strategies in TNBC. Key developments include the expansion of antibody-drug conjugates (ADCs) such as sacituzumab govitecan, which delivers cytotoxic payload directly to TROP-2-expressing tumor cells, and the consolidation of immune checkpoint inhibitors — particularly PD-L1 pathway blockade with agents like pembrolizumab — into neoadjuvant and metastatic settings. The review also addresses PARP inhibitors for BRCA1/2-mutated TNBC and emerging targets including androgen receptors and PI3K/AKT pathway components, outlining how molecular stratification is gradually replacing the historical "one chemotherapy fits all" approach.
The broader significance here is architectural: TNBC is being disaggregated into actionable molecular subtypes for the first time at clinical scale. Yet the review's framing as a comprehensive overview rather than a primary data study carries inherent limitations — it synthesizes existing trial evidence rather than generating new efficacy or safety data, so the conclusions reflect the current literature's known biases, including underrepresentation of older patients and diverse ancestries in foundational trials. Practically, the most durable gains so far appear concentrated in early-stage disease with high tumor-mutational burden or PD-L1 positivity. For metastatic TNBC, prognosis remains sobering. This is a solid confirmatory synthesis of an evolving field — incremental rather than paradigm-shifting, but clinically important as a roadmap for how combination strategies may be sequenced.